Back to Agenda
Session 2: Plenary Session: When Innovation and Need Meet: Development of COVID-19 mRNA Vaccines
Session Chair(s)
Scott Henry, PhD
Senior Vice President, Nonclinical Development, Ionis Pharmaceuticals, Inc., United States
The mRNA vaccine efforts took a giant leap forward with the success of the COVID-19 vaccine programs at Moderna and Pfizer/BioNTech in 2020. This herculean effort was accomplished through not only technological innovation, but the close and collaborative interaction with Regulatory Agencies to make the process as efficient as possible. This session will present some of the experience and lessons-learned from the perspective of the clinical trial management, CMC manufacturing, and review of dossiers.
Speaker(s)
Peter Marks, MD, PhD
Senior Vice President, Molecul, Eli Lilly and Company, United States
Preparing the Field: Efforts to Expedite COVID-19 Vaccine Development
Jacqueline Miller, MD
Senior Vice President, Therapeutic Area Head, Infectious Diseases, Moderna, United States
Presentation
Paul Rohlfing
Executive Director, Global CMC, Regulatory Affairs, Pfizer, Inc., United States
Vaccine Development at the Speed of Science
Have an account?